RxDoctor Payments Data

Joseph Calhoun, DO

Internal Medicine · Gibsonia, PANPI 1558346114

Payments from drug & device makers

$346in general payments, 2019–2025

Across 13 payments — averaging $26.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$145
  • GSK$76
  • Pfizer$55
  • Eisai Inc.$22
  • Abbott$21
  • Exact Sciences$15
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$346100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$346 in reported general payments places this provider in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$78,897
Medicare patients
204
Services billed
1,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban195$196,627
JardianceEmpagliflozin127$163,280
OzempicSemaglutide105$146,901
XareltoRivaroxaban86$118,311
MounjaroTirzepatide61$65,203
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$57,617
TradjentaLinagliptin49$51,791
Breo ElliptaFluticasone/Vilanterol76$42,981
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$19,145
TrulicityDulaglutide18$17,831
Fluticasone-SalmeterolFluticasone Propion/Salmeterol48$8,565
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$7,531
Rosuvastatin Calcium571$6,852
Repatha SureclickEvolocumab11$5,653
Humalog Kwikpen U-100Insulin Lispro15$5,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$55$196,627195 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$76$119,743178 claims
AbbVieSynthroid$13$4,63878 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Gibsonia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →